Literature DB >> 17177967

Severe fibrosis in hepatitis C virus-infected patients is associated with increased activity of the mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complex.

K S Brown1, M J Keogh, N Tagiuri, M J Grainge, J S Presanis, S D Ryder, W L Irving, J K Ball, R B Sim, T P Hickling.   

Abstract

Mannan-binding lectin (MBL) binds microorganisms via interactions with glycans on the target surface. Bound MBL subsequently activates MBL-associated serine protease proenzymes (MASPs). A role for MBL in hepatitis C virus (HCV) infection had been indicated by previous studies examining MBL levels and polymorphisms in relation to disease progression and response to treatment. We undertook this study to investigate a possible relationship between disease progression and functional MBL/MASP-1 complex activity. A functional assay for MBL/MASP-1 complex activity was employed to examine serum samples from patients with chronic HCV infection, non-HCV liver disease and healthy controls. Intrapatient consistency of MBL/MASP-1 complex activity levels was assessed in sequential samples from a subgroup of patients. Median values of MBL/MASP-1 complex activity were higher in sera from patients with liver disease compared with healthy controls. MBL/MASP-1 complex activity levels correlate with severity of fibrosis after adjusting for confounding factors (P = 0.003). MBL/MASP-1 complex activity was associated more significantly with fibrosis than was MBL concentration. The potential role of MBL/MASP-1 complex activity in disease progression is worthy of further study to investigate possible mechanistic links.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17177967      PMCID: PMC1810446          DOI: 10.1111/j.1365-2249.2006.03264.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  43 in total

Review 1.  Structure and biology of mannan-binding protein, MBP, an important component of innate immunity.

Authors:  T Kawasaki
Journal:  Biochim Biophys Acta       Date:  1999-12-06

2.  The epidemiology of hepatitis C in a UK health regional population of 5.12 million.

Authors:  A H Mohsen
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

3.  Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium.

Authors: 
Journal:  J Viral Hepat       Date:  1999-01       Impact factor: 3.728

4.  Mannose-binding lectin polymorphisms in patients with hepatitis C virus infection.

Authors:  K Sasaki; A Tsutsumi; N Wakamiya; K Ohtani; Y Suzuki; Y Watanabe; N Nakayama; T Koike
Journal:  Scand J Gastroenterol       Date:  2000-09       Impact factor: 2.423

5.  Disease-associated mutations in human mannose-binding lectin compromise oligomerization and activity of the final protein.

Authors:  Flemming Larsen; Hans O Madsen; Robert B Sim; Claus Koch; Peter Garred
Journal:  J Biol Chem       Date:  2004-02-05       Impact factor: 5.157

6.  Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study.

Authors:  S D Ryder; W L Irving; D A Jones; K R Neal; J C Underwood
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

7.  Fibrin in peritonitis. III. The mechanism of bacterial trapping by polymerizing fibrin.

Authors:  D L Dunn; R L Simmons
Journal:  Surgery       Date:  1982-09       Impact factor: 3.982

8.  Phagocytosis of Porphyromonas gingivalis and Prevotella intermedia by human polymorphonuclear leukocytes in clots formed from human plasma or purified fibrinogen.

Authors:  T J Hurst; J M Wilton
Journal:  J Periodontal Res       Date:  1992-03       Impact factor: 4.419

9.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.

Authors:  R G Knodell; K G Ishak; W C Black; T S Chen; R Craig; N Kaplowitz; T W Kiernan; J Wollman
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

10.  Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease.

Authors:  M Matsushita; T Fujita
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

View more
  15 in total

1.  Serum complement C4a and its relation to liver fibrosis in children with chronic hepatitis C.

Authors:  Behairy E Behairy; Ghada M El-Mashad; Ragab S Abd-Elghany; Enas M Ghoneim; Mostafa M Sira
Journal:  World J Hepatol       Date:  2013-08-27

2.  Hepatitis C Virus-related Mixed Cryoglobulinemia: Pathogenesis, Clinica Manifestations, and New Therapies.

Authors:  Neal J Schamberg; Gerond V Lake-Bakaar
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-09

3.  Gene expression profiling indicates the roles of host oxidative stress, apoptosis, lipid metabolism, and intracellular transport genes in the replication of hepatitis C virus.

Authors:  Samantha Blackham; Andrew Baillie; Fadel Al-Hababi; Katja Remlinger; Shihyun You; Robert Hamatake; Michael J McGarvey
Journal:  J Virol       Date:  2010-03-03       Impact factor: 5.103

4.  Serum ficolin-2 concentrations are significantly changed in patients with hepatitis B virus infection and liver diseases.

Authors:  Tielong Chen; Yilan Hu; Quanquan Ding; Jing Yu; Fubing Wang; Fengling Luo; Xiao-Lian Zhang
Journal:  Virol Sin       Date:  2015-07-23       Impact factor: 4.327

5.  Mannose-binding lectin MBL2 gene polymorphisms and outcome of hepatitis C virus-infected patients.

Authors:  Eirini Koutsounaki; George N Goulielmos; Mary Koulentaki; Christianna Choulaki; Elias Kouroumalis; Emmanouil Galanakis
Journal:  J Clin Immunol       Date:  2008-07-01       Impact factor: 8.317

6.  Mannan-binding lectin MBL2 gene polymorphism in chronic hepatitis C: association with the severity of liver fibrosis and response to interferon therapy.

Authors:  M L Alves Pedroso; A B W Boldt; L Pereira-Ferrari; R Steffensen; E Strauss; J C Jensenius; S O Ioshii; I Messias-Reason
Journal:  Clin Exp Immunol       Date:  2008-03-10       Impact factor: 4.330

7.  Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry.

Authors:  Kristelle S Brown; Michael J Keogh; Ania M Owsianka; Richard Adair; Arvind H Patel; James N Arnold; Jonathan K Ball; Robert B Sim; Alexander W Tarr; Timothy P Hickling
Journal:  Protein Cell       Date:  2010-07-29       Impact factor: 14.870

Review 8.  The role of humoral innate immunity in hepatitis C virus infection.

Authors:  Alexander W Tarr; Richard A Urbanowicz; Jonathan K Ball
Journal:  Viruses       Date:  2012-01-05       Impact factor: 5.048

9.  Serum mannan-binding lectin in egyptian patients with chronic hepatitis C: its relation to disease progression and response to treatment.

Authors:  Serag Esmat; Dalia Omran; Gihan A Sleem; Laila Rashed
Journal:  Hepat Mon       Date:  2012-04-30       Impact factor: 0.660

10.  Mannan binding lectin-associated serine protease 1 is induced by hepatitis C virus infection and activates human hepatic stellate cells.

Authors:  A Saeed; K Baloch; R J P Brown; R Wallis; L Chen; L Dexter; C P McClure; K Shakesheff; B J Thomson
Journal:  Clin Exp Immunol       Date:  2013-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.